Tenascin-C: Form versus function

Cell Adhesion and Migration

Volumn 9, Issue 1-2, 2015, Pages 48-82

  Giblin, Sean P ^a   Midwood, Kim S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biosynthesis; Cancer; Development; Glycosylation; Matrix assembly; Proteolytic cleavage; Splicing; Tenascin C; Therapeutics; Transcription

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBRONECTIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 2; NERVE GROWTH FACTOR; NEUROTROPHIN; SCATTER FACTOR; TENASCIN; VASCULOTROPIN;

CELL MIGRATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; GENE; GENE SEQUENCE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TNC GENE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TENASCIN;

EID: 84942060854     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/19336918.2014.987587     Document Type: Review

References (248)

1. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009; 3:287-310; http://dx.doi.org/10.1007/s12079-009-0075-1
2. Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS. Tenascins in stem cell niches. Matrix Biol 2014; 37C:112-23; http://dx.doi.org/10.1016/j.matbio.2014.01.007
3. Orend G, Saupe F, Schwenzer A, and Midwood, KS. The extracellular matrix and cancer: regulation of tumor cell biology by tenascin-C. iConcept Press 2014. ISBN: 978-1-922227-25-6.
4. Forsberg E, Hirsch E, Frohlich L, Meyer M, Ekblom P, Aszodi A, Werner S, Fassler R. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Nat Acad Sci USA 1996; 93:6594-9; http://dx.doi.org/10.1073/pnas.93.13.6594
5. Fukamauchi F, Wang YJ, Mataga N, Kusakabe M. Effects of cholecystokinin-B receptor antagonist on dopamine system in tenascin mutant mice. Neuroreport 1997; 8:3919-22; http://dx.doi.org/10.1097/00001756-199712220-00015
6. Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M. Tenascin-C promotes healing of Habu-snake venominduced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol 1998; 152:1237-45
7. Ohta M, Sakai T, Saga Y, Aizawa S, Saito M. Suppression of hematopoietic activity in tenascin-C-deficient mice. Blood 1998; 91:4074-83
8. Talts JF, Wirl G, Dictor M, Muller WJ, Fassler R. Tenascin-C modulates tumor stroma and monocyte/ macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 1999; 112(Pt 12):1855-64
9. Van Obberghen-Schilling E, Tucker RP, Saupe F, Gasser I, Cseh B, Orend G. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol 2011; 55:511-25; http://dx.doi.org/10.1387/ijdb.103243eo
10. Saupe F, Schwenzer A, Jia Y, Gasser I, Spenle C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep 2013; 5:482-92; http://dx.doi.org/10.1016/j.celrep.2013.09.014
11. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80; http://dx.doi.org/10.1038/nm.1987
12. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K. Deficiency of tenascin-C attenuates liver fibrosis in immunemediated chronic hepatitis in mice. J Pathol 2007; 211:86-94; http://dx.doi.org/10.1002/path.2099
13. Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D’Alessandro-Gabazza CN, Bruno NE, Takagi T, Hayashi T, Maruyama J, Maruyama K, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 2006; 36:3334-45; http://dx.doi.org/10.1002/eji.200636271
14. Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol 2011; 3(5).
15. Mackie EJ, Tucker RP. The tenascin-C knockout revisited. J Cell Sci 1999; 112(Pt 22):3847-53
16. Mokone GG, Gajjar M, September AV, Schwellnus MP, Greenberg J, Noakes TD, Collins M. The guanine-thymine dinucleotide repeat polymorphism within the tenascin-C gene is associated with achilles tendon injuries. Am J Sports Med 2005; 33:1016-21; http://dx.doi.org/10.1177/0363546504271986
17. Zhao Y, Zhao F, Zong L, Zhang P, Guan L, Zhang J, Wang D, Wang J, Chai W, Lan L, et al. Exome sequencing and linkage analysis identified tenascin-C (TNC) as a novel causative gene in nonsyndromic hearing loss. PloS One 2013; 8:e69549; http://dx.doi.org/10.1371/journal.pone.0069549
18. Matsuda A, Hirota T, Akahoshi M, Shimizu M, Tamari M, Miyatake A, Takahashi A, Nakashima K, Takahashi N, Obara K, et al. Coding SNP in tenascin-C Fn-III-D domain associates with adult asthma. Hum Mol Genet 2005; 14:2779-86; http://dx.doi.org/10.1093/hmg/ddi311
19. Gulcher JR, Alexakos MJ, Le Beau MM, Lemons RS, Stefansson K. Chromosomal localization of the human hexabrachion (tenascin) gene and evidence for recent reduplication within the gene. Genomics 1990; 6:616-22; http://dx.doi.org/10.1016/0888-7543(90)90495-G
20. Rocchi M, Archidiacono N, Romeo G, Saginati M, Zardi L. Assignment of the gene for human tenascin to the region q32-q34 of chromosome 9. Hum Genet 1991; 86:621-3
21. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011; 31:115-45; http://dx.doi.org/10.1615/CritRevImmunol.v31.i2.30
22. Jones FS, Burgoon MP, Hoffman S, Crossin KL, Cunningham BA, Edelman GM. A cDNA clone for cytotactin contains sequences similar to epidermal growth factor-like repeats and segments of fibronectin and fibrinogen. Proc Nat Acad Sci U S A 1988; 85:2186-90; http://dx.doi.org/10.1073/pnas.85.7.2186
23. Gulcher JR, Nies DE, Marton LS, Stefansson K. An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites. Proc Nat Acad Sci U S A 1989; 86:1588-92; http://dx.doi.org/10.1073/pnas.86.5.1588
24. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218:235-59; http://dx.doi.org/10.1002/(SICI)1097-0177(200006) 218:2%3c235::AID-DVDY2%3e3.0.CO;2-G
25. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5; http://dx.doi.org/10.1038/ng.259
26. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, Madugundu AK, Kelkar DS, Isserlin R, Jain S, et al. A draft map of the human proteome. Nature 2014; 509:575-81; http://dx.doi.org/10.1038/nature13302
27. Sriramarao P, Bourdon MA. A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Res 1993; 21:163-8; http://dx.doi.org/10.1093/nar/21.1.163
28. Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA. Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer 1997; 72:236-40; http://dx.doi.org/10.1002/(SICI)1097-0215(19970717)72:2%3c236::AID-IJC6%3e3.0.CO;2-S
29. Tucker RP, Spring J, Baumgartner S, Martin D, Hagios C, Poss PM, Chiquet-Ehrismann R. Novel tenascin variants with a distinctive pattern of expression in the avian embryo. Development 1994; 120:637-47
30. Gulcher JR, Nies DE, Alexakos MJ, Ravikant NA, Sturgill ME, Marton LS, Stefansson K. Structure of the human hexabrachion (tenascin) gene. Proc Nat Acad Sci U S A 1991; 88:9438-42; http://dx.doi.org/10.1073/pnas.88.21.9438
31. Joester A, Faissner A. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. J Biol Chem 1999; 274:17144-51; http://dx.doi.org/10.1074/jbc.274.24.17144
32. Garwood J, Theocharidis U, Calco V, Dobbertin A, Faissner A. Existence of tenascin-C isoforms in rat that contain the alternatively spliced AD1 domain are developmentally regulated during hippocampal development. Cell Mol Neurobiol 2012; 32:279-87; http://dx.doi.org/10.1007/s10571-011-9759-1
33. Joester A, Faissner A. The structure and function of tenascins in the nervous system. Matrix Biol 2001; 20:13-22; http://dx.doi.org/10.1016/S0945-053X(00)00136-0
34. Saga Y, Tsukamoto T, Jing N, Kusakabe M, Sakakura T. Murine tenascin: cDNA cloning, structure and temporal expression of isoforms. Gene 1991; 104:177-85; http://dx.doi.org/10.1016/0378-1119(91)90248-A
35. Ocklind G, Talts J, Fassler R, Mattsson A, Ekblom P. Expression of tenascin in developing and adult mouse lymphoid organs. J Histochem Cytochem 1993; 41:1163-9; http://dx.doi.org/10.1177/41.8.7687262
36. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986; 47:131-9; http://dx.doi.org/10.1016/0092-8674(86)90374-0
37. Chiquet M, Vrucinic-Filipi N, Schenk S, Beck K, Chiquet-Ehrismann R. Isolation of chick tenascin variants and fragments. A C-terminal heparin-binding fragment produced by cleavage of the extra domain from the largest subunit splicing variant. Eur J Biochem 1991; 199:379-88
38. Spring J, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments. Cell 1989; 59:325-34; http://dx.doi.org/10.1016/0092-8674(89)90294-8
39. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M. Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul 1991; 2:927-38
40. Weller A, Beck S, Ekblom P. Amino acid sequence of mouse tenascin and differential expression of two tenascin isoforms during embryogenesis. J Cell Biol 1991; 112:355-62; http://dx.doi.org/10.1083/jcb.112.2.355
41. Chiquet M, Fambrough DM. Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis. J Cell Biol 1984; 98:1926-36; http://dx.doi.org/10.1083/jcb.98.6.1926
42. Chiquet M, Fambrough DM. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol 1984; 98:1937-46; http://dx.doi.org/10.1083/jcb.98.6.1937
43. Hoffman S, Crossin KL, Edelman GM. Molecular forms, binding functions, and developmental expression patterns of cytotactin and cytotactin-binding proteoglycan, an interactive pair of extracellular matrix molecules. J Cell Biol 1988; 106:519-32; http://dx.doi.org/10.1083/jcb.106.2.519
44. Prieto AL, Jones FS, Cunningham BA, Crossin KL, Edelman GM. Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization. J Cell Biol 1990; 111:685-98; http://dx.doi.org/10.1083/jcb.111.2.685
45. Mackie EJ, Tucker RP. Tenascin in bone morphogenesis: expression by osteoblasts and cell type-specific expression of splice variants. J Cell Sci 1992; 103(Pt 3):765-71
46. Tucker RP. The in situ localization of tenascin splice variants and thrombospondin 2 mRNA in the avian embryo. Development 1993; 117:347-58
47. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci 1993; 104(Pt 1):69-76
48. Tucker RP, McKay SE. The expression of tenascin by neural crest cells and glia. Development 1991; 112:1031-9
49. Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R, Spence J, Tucker RP. The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation 1997; 62:71-82; http://dx.doi.org/10.1046/j.1432-0436.1997.6220071.x
50. Kaplony A, Zimmermann DR, Fischer RW, Imhof BA, Odermatt BF, Winterhalter KH, Vaughan L. Tenascin Mr 220,000 isoform expression correlates with corneal cell migration. Development 1991; 112:605-14
51. Pacifici M, Iwamoto M, Golden EB, Leatherman JL, Lee YS, Chuong CM. Tenascin is associated with articular cartilage development. Dev Dyn 1993; 198:123-34; http://dx.doi.org/10.1002/aja.1001980206
52. Anstrom KK, Tucker RP. Tenascin-C lines the migratory pathways of avian primordial germ cells and hematopoietic progenitor cells. Dev Dyn 1996; 206:437-46; http://dx.doi.org/10.1002/(SICI)1097-0177(199608)206:4%3c437::AID-AJA9%3e3.0.CO;2-J
53. Aufderheide E, Ekblom P. Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions. J Cell Biol 1988; 107:2341-9; http://dx.doi.org/10.1083/jcb.107.6.2341
54. Young SL, Chang LY, Erickson HP. Tenascin-C in rat lung: distribution, ontogeny and role in branching morphogenesis. Dev Biol 1994; 161:615-25; http://dx.doi.org/10.1006/dbio.1994.1057
55. Zhao Y, Young SL. TGF-b regulates expression of tenascin alternative-splicing isoforms in fetal rat lung. Am J Physiol 1995; 268:L173-80
56. Dorries U, Schachner M. Tenascin mRNA isoforms in the developing mouse brain. J Neurosci Res 1994; 37:336-47; http://dx.doi.org/10.1002/jnr.490370306
57. Bartsch S, Bartsch U, Dorries U, Faissner A, Weller A, Ekblom P, Schachner M. Expression of tenascin in the developing and adult cerebellar cortex. J Neurosci 1992; 12:736-49
58. Zisch AH, D’Alessandri L, Ranscht B, Falchetto R, Winterhalter KH, Vaughan L. Neuronal cell adhesion molecule contactin/F11 binds to tenascin via its immunoglobulin-like domains. J Cell Biol 1992; 119:203-13; http://dx.doi.org/10.1083/jcb.119.1.203
59. Vaughan L, Weber P, D’Alessandri L, Zisch AH, Winterhalter KH. Tenascin-contactin/F11 interactions: a clue for a developmental role? Perspect Dev Neurobiol 1994; 2:43-52
60. Weber P, Ferber P, Fischer R, Winterhalter KH, Vaughan L. Binding of contactin/F11 to the fibronectin type III domains 5 and 6 of tenascin is inhibited by heparin. FEBS Lett 1996; 389:304-8; http://dx.doi.org/10.1016/0014-5793(96)00609-6
61. Ghert MA, Qi WN, Erickson HP, Block JA, Scully SP. Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Struct Funct 2001; 26:179-87; http://dx.doi.org/10.1247/csf.26.179
62. Crossin KL, Hoffman S, Tan SS, Edelman GM. Cytotactin and its proteoglycan ligand mark structural and functional boundaries in somatosensory cortex of the early postnatal mouse. Dev Biol 1989; 136:381-92; http://dx.doi.org/10.1016/0012-1606(89)90264-9
63. Steindler DA, Cooper NG, Faissner A, Schachner M. Boundaries defined by adhesion molecules during development of the cerebral cortex: the J1/tenascin glycoprotein in the mouse somatosensory cortical barrel field. Dev Biol 1989; 131:243-60; http://dx.doi.org/10.1016/S0012-1606(89)80056-9
64. Meiners S, Geller HM. Long and short splice variants of human tenascin differentially regulate neurite outgrowth. Mol and Cell Neurosci 1997; 10:100-16; http://dx.doi.org/10.1006/mcne.1997.0643
65. Garcion E, Faissner A, ffrench-Constant C. Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development 2001; 128:2485-96
66. Gates MA, Thomas LB, Howard EM, Laywell ED, Sajin B, Faissner A, Gotz B, Silver J, Steindler DA. Cell and molecular analysis of the developing and adult mouse subventricular zone of the cerebral hemispheres. J Comp Neurol 1995; 361:249-66; http://dx.doi.org/10.1002/cne.903610205
67. Treloar HB, Ray A, Dinglasan LA, Schachner M, Greer CA. Tenascin-C is an inhibitory boundary molecule in the developing olfactory bulb. J Neurosci 2009; 29:9405-16; http://dx.doi.org/10.1523/JNEUROSCI.2356-09.2009
68. Garcion E, Halilagic A, Faissner A, ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 2004; 131:3423-32; http://dx.doi.org/10.1242/dev.01202
69. von Holst A, Egbers U, Prochiantz A, Faissner A. Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. J Biol Chem 2007; 282:9172-81; http://dx.doi.org/10.1074/jbc.M608067200
70. Moritz S, Lehmann S, Faissner A, von Holst A. An induction gene trap screen in neural stem cells reveals an instructive function of the niche and identifies the splicing regulator sam68 as a tenascin-C-regulated target gene. Stem Cells 2008; 26:2321-31; http://dx.doi.org/10.1634/stemcells.2007-1095
71. Yagi H, Yanagisawa M, Suzuki Y, Nakatani Y, Ariga T, Kato K, Yu RK. HNK-1 epitope-carrying tenascin-C spliced variant regulates the proliferation of mouse embryonic neural stem cells. J Biol Chem 2010; 285:37293-301; http://dx.doi.org/10.1074/jbc.M110.157081
72. Kruse J, Keilhauer G, Faissner A, Timpl R, Schachner M. The J1 glycoprotein–a novel nervous system cell adhesion molecule of the L2/HNK-1 family. Nature 1985; 316:146-8; http://dx.doi.org/10.1038/316146a0
73. McGarry RC, Helfand SL, Quarles RH, Roder JC. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 1983; 306:376-8; http://dx.doi.org/10.1038/306376a0
74. Kruse J, Mailhammer R, Wernecke H, Faissner A, Sommer I, Goridis C, Schachner M. Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. Nature 1984; 311:153-5; http://dx.doi.org/10.1038/311153a0
75. Nieke J, Schachner M. Expression of the neural cell adhesion molecules L1 and N-CAM and their common carbohydrate epitope L2/HNK-1 during development and after transection of the mouse sciatic nerve. Differentiation 1985; 30:141-51; http://dx.doi.org/10.1111/j.1432-0436.1985.tb00525.x
76. Gotz B, Scholze A, Clement A, Joester A, Schutte K, Wigger F, Frank R, Spiess E, Ekblom P, Faissner A. Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons. J Cell Biol 1996; 132:681-99; http://dx.doi.org/10.1083/jcb.132.4.681
77. Husmann K, Faissner A, Schachner M. Tenascin promotes cerebellar granule cell migration and neurite outgrowth by different domains in the fibronectin type III repeats. J Cell Biol 1992; 116:1475-86; http://dx.doi.org/10.1083/jcb.116.6.1475
78. Mercado ML, Nur-e-Kamal A, Liu HY, Gross SR, Movahed R, Meiners S. Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal alpha7beta1 integrin. J Neurosci 2004; 24:238-47; http://dx.doi.org/10.1523/JNEUROSCI.4519-03.2004
79. Gotz M, Bolz J, Joester A, Faissner A. Tenascin-C synthesis and influence on axonal growth during rat cortical development. Eur J Neurosci 1997; 9:496-506; http://dx.doi.org/10.1111/j.1460-9568.1997.tb01627.x
80. Sahlberg C, Aukhil I, Thesleff I. Tenascin-C in developing mouse teeth: expression of splice variants and stimulation by TGFbeta and FGF. Eur J Oral Sci 2001; 109:114-24; http://dx.doi.org/10.1034/j.1600-0722.2001.00990.x
81. Jones PL, Boudreau N, Myers CA, Erickson HP, Bissell MJ. Tenascin-C inhibits extracellular matrixdependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. J Cell Sci 1995; 108(Pt 2):519-27
82. Wehrle B, Chiquet M. Tenascin is accumulated along developing peripheral nerves and allows neurite outgrowth in vitro. Development 1990; 110:401-15
83. Perez RG, Halfter W. Tenascin in the developing chick visual system: distribution and potential role as a modulator of retinal axon growth. Dev Biol 1993; 156:278-92; http://dx.doi.org/10.1006/dbio.1993.1076
84. Bartsch S, Husmann K, Schachner M, Bartsch U. The extracellular matrix molecule tenascin: expression in the developing chick retinotectal system and substrate properties for retinal ganglion cell neurites in vitro. Eur J Neurosci 1995; 7:907-16; http://dx.doi.org/10.1111/j.1460-9568.1995.tb01078.x
85. Phillips GR, Edelman GM, Crossin KL. Separate cell binding sites within cytotactin/tenascin differentially promote neurite outgrowth. Cell Adhes Commun 1995; 3:257-71; http://dx.doi.org/10.3109/15419069509081291
86. Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 1997; 8:2055-75; http://dx.doi.org/10.1091/mbc.8.10.2055
87. Adams JC, Lawler J. Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. Mol Biol Cell 1994; 5:423-37; http://dx.doi.org/10.1091/mbc.5.4.423
88. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 1994; 126:539-48; http://dx.doi.org/10.1083/jcb.126.2.539
89. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7:883-92; http://dx.doi.org/10.1091/mbc.7.6.883
90. Meiners S, Mercado ML, Nur-e-Kamal MS, Geller HM. Tenascin-C contains domains that independently regulate neurite outgrowth and neurite guidance. J Neurosci 1999; 19:8443-53
91. Rigato F, Garwood J, Calco V, Heck N, Faivre-Sarrailh C, Faissner A. Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. J Neurosci 2002; 22:6596-609
92. Lochter A, Vaughan L, Kaplony A, Prochiantz A, Schachner M, Faissner A. J1/tenascin in substratebound and soluble form displays contrary effects on neurite outgrowth. J Cell Biol 1991; 113:1159-71; http://dx.doi.org/10.1083/jcb.113.5.1159
93. Meiners S, Powell EM, Geller HM. Neurite outgrowth promotion by the alternatively spliced region of tenascin-C is influenced by cell-type specific binding. Matrix Biol 1999; 18:75-87; http://dx.doi.org/10.1016/S0945-053X(98)00008-0
94. Siddiqui S, Horvat-Brocker A, Faissner A. The glia-derived extracellular matrix glycoprotein tenascin-C promotes embryonic and postnatal retina axon outgrowth via the alternatively spliced fibronectin type III domain TNfnD. Neuron Glia Biol 2008; 4:271-83; http://dx.doi.org/10.1017/S1740925X09990020
95. Michele M, Faissner A. Tenascin-C stimulates contactin-dependent neurite outgrowth via activation of phospholipase C. Mol and Cell Neurosci 2009; 41:397-408; http://dx.doi.org/10.1016/j.mcn.2009.04.004
96. Bell SC, Pringle JH, Taylor DJ, Malak TM. Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Mol Hum Reprod 1999; 5:1066-76; http://dx.doi.org/10.1093/molehr/5.11.1066
97. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270:8650-4; http://dx.doi.org/10.1074/jbc.270.15.8650
98. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244:143-63; http://dx.doi.org/10.1016/j.canlet.2006.02.017
99. Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 1990; 63:798-806
100. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992; 52:688-92; http://dx.doi.org/10.1002/ijc.2910520504
101. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Qualitative and quantitative changes of human tenascin expression in transformed lung fibroblast and lung tumor tissues: comparison with fibronectin. Cancer Res 1991; 51:4876-81
102. Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen I. Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 1995; 63:442-9; http://dx.doi.org/10.1002/ijc.2910630324
103. Sakai T, Kawakatsu H, Hirota N, Yokoyama T, Sakakura T, Saito M. Specific expression of tenascin in human colonic neoplasms. Br J Cancer 1993; 67:1058-64; http://dx.doi.org/10.1038/bjc.1993.194
104. Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005; 47:17-29; http://dx.doi.org/10.1016/j.lungcan.2004.05.016
105. Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stocker G, et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest 1995; 73:172-82
106. Zirbes TK, Baldus SE, Moenig SP, Schmitz K, Thiele J, Holscher AH, Dienes HP. Tenascin expression in gastric cancer with special emphasis on the WHO-, Lauren-, and Goseki-classifications. Int J Mol Med 1999; 4:39-42
107. Ikeda Y, Mori M, Kajiyama K, Haraguchi Y, Sasaki O, Sugimachi K. Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes. Br J Cancer 1995; 72:189-92; http://dx.doi.org/10.1038/bjc.1995.301
108. Ilunga K, Iriyama K. Expression of tenascin in gastric carcinoma. Br J Surg 1995; 82:948-51; http://dx.doi.org/10.1002/bjs.1800820730
109. Atula T, Hedstrom J, Finne P, Leivo I, Markkanen-Leppanen M, Haglund C. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. Anticancer Res 2003; 23:3051-6
110. Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 2004; 57:1151-5; http://dx.doi.org/10.1136/jcp.2003.015818
111. Pilch H, Schaffer U, Schlenger K, Lautz A, Tanner B, Hockel M, Knapstein PG. Expression of tenascin in human cervical cancer–association of tenascin expression with clinicopathological parameters. Gynecol Oncol 1999; 73:415-21; http://dx.doi.org/10.1006/gyno.1999.5405
112. Moch H, Torhorst J, Durmuller U, Feichter GE, Sauter G, Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Pract 1993; 189:510-4; http://dx.doi.org/10.1016/S0344-0338(11)80357-2
113. Sugawara I, Hirakoshi J, Masunaga A, Itoyama S, Sakakura T. Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion Metastasis 1991; 11:325-31
114. Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4%3c475::AID-PATH462%3e3.0.CO;2-V
115. Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004; 203:771-9; http://dx.doi.org/10.1002/path.1589
116. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999; 154:1345-52; http://dx.doi.org/10.1016/S0002-9440(10)65388-6
117. Viale GL, Castellani P, Dorcaratto A, Pau A, Sehrbundt E, Siri A, Biro A, Zardi L. Occurrence of a glioblastoma-associated tenascin-C isoform in cerebral cavernomas and neighboring vessels. Neurosurgery 2002; 50:838-42; discussion 42; http://dx.doi.org/10.1097/00006123-200204000-00028
118. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006; 19:471-8; http://dx.doi.org/10.1093/protein/gzl033
119. Franz M, Hansen T, Borsi L, Geier C, Hyckel P, Schleier P, Richter P, Altendorf-Hofmann A, Kosmehl H, Berndt A. A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/ gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy. J Oral Pathol Med 2007; 36:6-11; http://dx.doi.org/10.1111/j.1600-0714.2006.00492.x
120. Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, et al. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006; 132:537-46; http://dx.doi.org/10.1007/s00432-006-0106-8
121. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97
122. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 2003; 162:1857-67; http://dx.doi.org/10.1016/S0002-9440(10)64320-9
123. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA. Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res 2010; 12:R57
124. Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev 2010; 29:595-606; http://dx.doi.org/10.1007/s10555-010-9249-9
125. Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A. Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 1999; 82:477-83; http://dx.doi.org/10.1002/(SICI)1097-0215(19990812)82:4%3c477::AIDIJC2% 3e3.0.CO;2-5
126. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H. High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig 2007; 11:93-9; http://dx.doi.org/10.1007/s00784-006-0086-8
127. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991; 115:1127-36; http://dx.doi.org/10.1083/jcb.115.4.1127
128. Galoian KA, Garamszegi N, Garamszegi SP, Scully SP. Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential. Exp Biol Med 2007; 232:515-22
129. Chung CY, Zardi L, Erickson HP. Binding of tenascin-C to soluble fibronectin and matrix fibrils. J Biol Chem 1995; 270:29012-7; http://dx.doi.org/10.1074/jbc.270.48.29012
130. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res: BCR 2009; 11:R24
131. Tucker RP. Quantitative in situ localization of tenascin-C alternatively spliced transcripts in the avian optic tectum. Mol Vis 1998; 4:18
132. Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y, Ohwaki T, Nagao O, Kamiya S, Hayashi R, et al. A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem 2007; 282:34929-37; http://dx.doi.org/10.1074/jbc.M705608200
133. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 2002; 8:1152-6
134. Tanaka R, Seki Y, Saito Y, Kamiya S, Fujita M, Okutsu H, Iyoda T, Takai T, Owaki T, Yajima H, et al. Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin alpha5beta1. J Biol Chem 2014; 289:17699-708; http://dx.doi.org/10.1074/jbc.M113.546622
135. Gong XG, Lv YF, Li XQ, Xu FG, Ma QY. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol Pharm Bull 2010; 33:1261-7; http://dx.doi.org/10.1248/bpb.33.1261
136. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochimi Biophys Acta 2011; 1813:1978-86; http://dx.doi.org/10.1016/j.bbamcr.2011.03.010
137. Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006; 208:673-85; http://dx.doi.org/10.1002/path.1935
138. Riedl S, Bodenmuller H, Hinz U, Holle R, Moller P, Schlag P, Herfarth C, Faissner A. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer 1995; 64:65-9; http://dx.doi.org/10.1002/ijc.2910640113
139. Riedl S, Tandara A, Reinshagen M, Hinz U, Faissner A, Bodenmuller H, Buhr HJ, Herfarth C, Moller P. Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 2001; 16:285-91; http://dx.doi.org/10.1007/s003840100312
140. Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol 2003; 28:515-20; http://dx.doi.org/10.1046/j.1365-2230.2003.01326.x
141. Schenk S, Bruckner-Tuderman L, Chiquet-Ehrismann R. Dermo-epidermal separation is associated with induced tenascin expression in human skin. Br J Dermatol 1995; 133:13-22; http://dx.doi.org/10.1111/j.1365-2133.1995.tb02486.x
142. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005; 25:489-95
143. Didem T, Faruk T, Senem K, Derya D, Murat S, Murat G, Oznur K. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer. Tumour Biol 2014; 35:6777-82; http://dx.doi.org/10.1007/s13277-014-1923-z
144. Tastekin D, Tas F, Karabulut S, Duranyildiz D, Serilmez M, Guveli M, Vatansever S. Clinical significance of serum tenascin-C levels in breast cancer. Tumour Biol 2014; 35:6619-25; http://dx.doi.org/10.1007/s13277-014-1875-3
145. Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. Int J Cancer 1995; 61:443-9; http://dx.doi.org/10.1002/ijc.2910610402
146. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. World J Surg 2007; 31:388-94; http://dx.doi.org/10.1007/s00268-006-0328-6
147. Takeda A, Otani Y, Hirooka E, Okada K, Torii T, Shinozuka N, Koyama I. Plasma large Tenascin-C spliced variant as a possible biomarker for the prediction of hepatic recurrence in colorectal cancer. Surgery 2007; 141:124-5; http://dx.doi.org/10.1016/j.surg.2006.07.044
148. Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009; 135:1351-8; http://dx.doi.org/10.1007/s00432-009-0576-6
149. Gecks T, Junker K, Franz M, Richter P, Walther M, Voigt A, Neri D, Kosmehl H, Wunderlich H, Kiehntopf M, et al. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? Clin Chim Acta 2011; 412:1931-6; http://dx.doi.org/10.1016/j.cca.2011.06.038
150. Brellier F, Martina E, Degen M, Heuze-Vourc’h N, Petit A, Kryza T, Courty Y, Terracciano L, Ruiz C, Chiquet-Ehrismann R. Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors. BMC Clin Pathol 2012; 12:14; http://dx.doi.org/10.1186/1472-6890-12-14
151. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005; 46:1042-51
152. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Jo Clin Oncol 2000; 18:3862-72
153. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10:767-77; http://dx.doi.org/10.1038/nrd3554
154. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200-8; http://dx.doi.org/10.1158/1078-0432.CCR-05-2804
155. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D, Bello L. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 2010; 103:827-36; http://dx.doi.org/10.1038/sj.bjc.6605832
156. Saghizadeh M, Khin HL, Bourdon MA, Kenney MC, Ljubimov AV. Novel splice variants of human tenascin-C mRNA identified in normal and bullous keratopathy corneas. Cornea 1998; 17:326-32; http://dx.doi.org/10.1097/00003226-199805000-00014
157. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 1998; 39:1135-42
158. Pearson CA, Pearson D, Shibahara S, Hofsteenge J, Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-b. EMBO J 1988; 7:2977-82
159. Chimal-Monroy J, Diaz de Leon L. Expression of Ncadherin, N-CAM, fibronectin and tenascin is stimulated by TGF-beta1, beta2, beta3 and beta5 during the formation of precartilage condensations. Int J Dev Biol 1999; 43:59-67
160. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biophys Acta 2009; 1793:888-92; http://dx.doi.org/10.1016/j.bbamcr.2008.12.012
161. Akhurst RJ, Lehnert SA, Faissner A, Duffie E. TGF b in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990; 108:645-56
162. Soini Y, Kamel D, Apaja-Sarkkinen M, Virtanen I, Lehto VP. Tenascin immunoreactivity in normal and pathological bone marrow. J Clin Pathol 1993; 46:218-21; http://dx.doi.org/10.1136/jcp.46.3.218
163. Suzuki S, Li AJ, Ikemoto M, Imamura T. Expression of tenascin-C long isoforms is induced in the hypothalamus by FGF-1. Neuroreport 2002; 13:1041-5; http://dx.doi.org/10.1097/00001756-200206120-00013
164. Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000; 292:446-54; http://dx.doi.org/10.1007/s004030000152
165. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C premRNA is controlled by the extracellular pH. J Biol Chem 1995; 270:6243-5; http://dx.doi.org/10.1074/jbc.270.11.6243
166. Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer 1996; 66:632-5; http://dx.doi.org/10.1002/(SICI)1097-0215(19960529)66:5%3c632::AID-IJC9%3e3.0.CO;2-U
167. Bumke MA, Neri D, Elia G. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study. Proteomics 2003; 3:675-88; http://dx.doi.org/10.1002/pmic.200300395
168. Jensen MA, Wilkinson JE, Krainer AR. Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nat Struct Mol Biol 2014; 21:189-97; http://dx.doi.org/10.1038/nsmb.2756
169. Taylor HC, Lightner VA, Beyer WF Jr., McCaslin D, Briscoe G, Erickson HP. Biochemical and structural studies of tenascin/hexabrachion proteins. J Cell Biochem 1989; 41:71-90; http://dx.doi.org/10.1002/jcb.240410204
170. Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, Engel J. Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiledcoil a-helices. J Biol Chem 1998; 273:10602-8; http://dx.doi.org/10.1074/jbc.273.17.10602
171. Redick SD, Schwarzbauer JE. Rapid intracellular assembly of tenascin hexabrachions suggests a novel cotranslational process. J Cell Sci 1995; 108(Pt 4):1761-9
172. Erickson HP, Inglesias JL. A six-armed oligomer isolated from cell surface fibronectin preparations. Nature 1984; 311:267-9; http://dx.doi.org/10.1038/311267a0
173. Luczak JA, Redick SD, Schwarzbauer JE. A single cysteine, Cys-64, is essential for assembly of tenascin-C hexabrachions. J Biol Chem 1998; 273:2073-7; http://dx.doi.org/10.1074/jbc.273.4.2073
174. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. (in preparation 2004).
175. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 2013; 32:1478-88; http://dx.doi.org/10.1038/emboj.2013.79
176. Vaughan L, Huber S, Chiquet M, Winterhalter KH. A major, six-armed glycoprotein from embryonic cartilage. EMBO J 1987; 6:349-53
177. Sano K, Asanuma-Date K, Arisaka F, Hattori S, Ogawa H. Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration. Glycobiology 2007; 17:784-94; http://dx.doi.org/10.1093/glycob/cwm031
178. Jones GE, Arumugham RG, Tanzer ML. Fibronectin glycosylation modulates fibroblast adhesion and spreading. J Cell Biol 1986; 103:1663-70; http://dx.doi.org/10.1083/jcb.103.5.1663
179. Sano K, Miyamoto Y, Kawasaki N, Hashii N, Itoh S, Murase M, Date K, Yokoyama M, Sato C, Kitajima K, et al. Survival signals of hepatic stellate cells in liver regeneration are regulated by glycosylation changes in rat vitronectin, especially decreased sialylation. J Biol Chem 2010; 285:17301-9; http://dx.doi.org/10.1074/jbc.M109.077016
180. Alisson-Silva F, Freire-de-Lima L, Donadio JL, Lucena MC, Penha L, Sa-Diniz JN, Dias WB, Todeschini AR. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelialmesenchymal transition of cultured human epithelial cells. PloS One 2013; 8:e60471; http://dx.doi.org/10.1371/journal.pone.0060471
181. Kasbaoui L, Harb J, Bernard S, Meflah K. Differences in glycosylation state of fibronectin from two rat colon carcinoma cell lines in relation to tumoral progressiveness. Cancer Res 1989; 49:5317-22
182. Chung CY, Erickson HP. Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J Cell Sci 1997; 110(Pt 12):1413-9
183. Ramos DM, Chen B, Regezi J, Zardi L, Pytela R. Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer 1998; 75:680-7; http://dx.doi.org/10.1002/(SICI)1097-0215(19980302)75:5%3c680::AID-IJC4%3e3.0.CO;2-V
184. Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M. Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci 1999; 40:1071-80
185. Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N, Kudo A. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010; 285:2028-39; http://dx.doi.org/10.1074/jbc.M109.051961
186. Rocco M, Carson M, Hantgan R, McDonagh J, Hermans J. Dependence of the shape of the plasma fibronectin molecule on solvent composition. Ionic strength and glycerol content. J Biol Chem 1983; 258:14545-9
187. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M. Tenascin interferes with fibronectin action. Cell 1988; 53:383-90; http://dx.doi.org/10.1016/0092-8674(88)90158-4
188. Hoffman S, Edelman GM. A proteoglycan with HNK-1 antigenic determinants is a neuron-associated ligand for cytotactin. Proc Nat Acad Sci U S A 1987; 84:2523-7; http://dx.doi.org/10.1073/pnas.84.8.2523
189. Ruggiero S, Cosgarea R, Potempa J, Potempa B, Eick S, Chiquet M. Cleavage of extracellular matrix in periodontitis: gingipains differentially affect cell adhesion activities of fibronectin and tenascin-C. Biochimi Biophys Acta 2013; 1832:517-26; http://dx.doi.org/10.1016/j.bbadis.2013.01.003
190. Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG. EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24:1416-21; http://dx.doi.org/10.1161/01.ATV.0000134299.89599.53
191. Chiao YA, Zamilpa R, Lopez EF, Dai Q, Escobar GP, Hakala K, Weintraub ST, Lindsey ML. In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res 2010; 9:2649-57; http://dx.doi.org/10.1021/pr100147r
192. Zamilpa R, Lopez EF, Chiao YA, Dai Q, Escobar GP, Hakala K, Weintraub ST, Lindsey ML. Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 2010; 10:2214-23; http://dx.doi.org/10.1002/pmic.200900587
193. Gueders MM, Hirst SJ, Quesada-Calvo F, Paulissen G, Hacha J, Gilles C, Gosset P, Louis R, Foidart JM, Lopez-Otin C, et al. Matrix metalloproteinase-19 deficiency promotes tenascin-C accumulation and allergen-induced airway inflammation. Am J Respir Cell Mol Biol 2010; 43:286-95; http://dx.doi.org/10.1165/rcmb.2008-0426OC
194. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, Duffin KL. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58:2420-31; http://dx.doi.org/10.1002/art.23654
195. Sofat N, Robertson SD, Hermansson M, Jones J, Mitchell P, Wait R. Tenascin-C fragments are endogenous inducers of cartilage matrix degradation. Rheumatol Int 2012; 32:2809-17; http://dx.doi.org/10.1007/s00296-011-2067-8
196. To WS, Midwood KS. Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol 2010; 29:573-85; http://dx.doi.org/10.1016/j.matbio.2010.08.003
197. Ambort D, Brellier F, Becker-Pauly C, Stocker W, Andrejevic-Blant S, Chiquet M, Sterchi EE. Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Matrix Biol 2010; 29:31-42; http://dx.doi.org/10.1016/j.matbio.2009.08.007
198. Iyer AK, Tran KT, Borysenko CW, Cascio M, Camacho CJ, Blair HC, Bahar I, Wells A. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J Cell Physiol 2007; 211:748-58; http://dx.doi.org/10.1002/jcp.20986
199. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001; 154:459-68; http://dx.doi.org/10.1083/jcb.200103103
200. Rodrigues M, Yates CC, Nuschke A, Griffith L, Wells A. The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng Part A 2013; 19:1972-83; http://dx.doi.org/10.1089/ten.tea.2012.0568
201. De Laporte L, Rice JJ, Tortelli F, Hubbell JA. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PloS One 2013; 8: e62076; http://dx.doi.org/10.1371/journal.pone.0062076
202. Schumacher S, Stube EM. Regulated binding of the fibrinogen-like domains of tenascin-R and tenascin-C to the neural EGF family member CALEB. J Neurochem 2003; 87:1213-23; http://dx.doi.org/10.1046/j.1471-4159.2003.02112.x
203. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010; 184:2655-62; http://dx.doi.org/10.4049/jimmunol.0903359
204. Latijnhouwers MA, Pfundt R, de Jongh GJ, Schalkwijk J. Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol 1998; 17:305-16; http://dx.doi.org/10.1016/S0945-053X(98)90083-X
205. Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. J Invest Dermatol 2006; 126:551-60; http://dx.doi.org/10.1038/sj.jid.5700090
206. Nakoshi Y, Hasegawa M, Sudo A, Yoshida T, Uchida A. Regulation of tenascin-C expression by tumor necrosis factor-a in cultured human osteoarthritis chondrocytes. J Rheumatol 2008; 35:147-52
207. Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Tenascin-C upregulation by transforming growth factor-b in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene 2004; 23:1656-67; http://dx.doi.org/10.1038/sj.onc.1207064
208. Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Platelet derived growth factor induced tenascin-C transcription is phosphoinositide 3-kinase/Aktdependent and mediated by Ets family transcription factors. J Cell Physiol 2006; 206:718-27; http://dx.doi.org/10.1002/jcp.20527
209. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, Lee RT. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J Biol Chem 1999; 274:21840-6; http://dx.doi.org/10.1074/jbc.274.31.21840
210. Asparuhova MB, Ferralli J, Chiquet M, Chiquet-Ehrismann R. The transcriptional regulator megakaryoblastic leukemia-1 mediates serum response factorindependent activation of tenascin-C transcription by mechanical stress. FASEB J 2011; 25:3477-88; http://dx.doi.org/10.1096/fj.11-187310
211. Scherer C, Pfisterer L, Wagner AH, Hodebeck M, Cattaruzza M, Hecker M, Korff T. Arterial wall stress controls NFAT5 activity in vascular smooth muscle cells. J Am Heart Assoc 2014; 3:e000626; http://dx.doi.org/10.1161/JAHA.113.000626
212. Jones FS, Chalepakis G, Gruss P, Edelman GM. Activation of the cytotactin promoter by the homeoboxcontaining gene Evx-1. Proc Nat Acad Sci U S A 1992; 89:2091-5; http://dx.doi.org/10.1073/pnas.89.6.2091
213. Chiquet-Ehrismann R, Tannheimer M, Koch M, Brunner A, Spring J, Martin D, Baumgartner S, Chiquet M. Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. J Cell Biol 1994; 127:2093-101; http://dx.doi.org/10.1083/jcb.127.6.2093
214. Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L. Human tenascin gene. Structure of the 5’-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem 1995; 270:3429-34; http://dx.doi.org/10.1074/jbc.270.7.3429
215. Copertino DW, Edelman GM, Jones FS. Multiple promoter elements differentially regulate the expression of the mouse tenascin gene. Proc Nat Acad Sci U S A 1997; 94:1846-51; http://dx.doi.org/10.1073/pnas.94.5.1846
216. Gherzi R, Briata P, Boncinelli E, Ponassi M, Querze G, Viti F, Corte G, Zardi L. The human homeodomain protein OTX2 binds to the human tenascin-C promoter and trans-represses its activity in transfected cells. DNA Cell Biol 1997; 16:559-67; http://dx.doi.org/10.1089/dna.1997.16.559
217. Mettouchi A, Cabon F, Montreau N, Dejong V, Vernier P, Gherzi R, Mercier G, Binetruy B. The c-Juninduced transformation process involves complex regulation of tenascin-C expression. Mol Cell Biol 1997; 17:3202-9
218. Jones PL, Jones FS, Zhou B, Rabinovitch M. Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci 1999; 112(Pt 4):435-45
219. Shirasaki F, Makhluf HA, LeRoy C, Watson DK, Trojanowska M. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 1999; 18:7755-64; http://dx.doi.org/10.1038/sj.onc.1203360
220. Jones FS, Meech R, Edelman DB, Oakey RJ, Jones PL. Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. Circ Res 2001; 89:131-8; http://dx.doi.org/10.1161/hh1401.093582
221. McKean DM, Sisbarro L, Ilic D, Kaplan-Alburquerque N, Nemenoff R, Weiser-Evans M, Kern MJ, Jones PL. FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration. J Cell Biol 2003; 161:393-402; http://dx.doi.org/10.1083/jcb.jcb.200302126
222. Ghatnekar A, Trojanowska M. GATA-6 is a novel transcriptional repressor of the human Tenascin-C gene expression in fibroblasts. Biochimi Biophys Acta 2008; 1779:145-51; http://dx.doi.org/10.1016/j.bbagrm.2007.11.012
223. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 2009; 69:458-65; http://dx.doi.org/10.1158/0008-5472.CAN-08-2610
224. Erickson HP, Taylor HC. Hexabrachion proteins in embryonic chicken tissues and human tumors. J Cell Biol 1987; 105:1387-94; http://dx.doi.org/10.1083/jcb.105.3.1387
225. Matsuoka Y, Spring J, Ballmer-Hofer K, Hofer U, Chiquet-Ehrismann R. Differential expression of tenascin splicing variants in the chick gizzard and in cell cultures. Cell Differ Dev 1990; 32:417-23; http://dx.doi.org/10.1016/0922-3371(90)90058-5
226. Koch M, Wehrle-Haller B, Baumgartner S, Spring J, Brubacher D, Chiquet M. Epithelial synthesis of tenascin at tips of growing bronchi and graded accumulation in basement membrane and mesenchyme. Exp Cell Res 1991; 194:297-300; http://dx.doi.org/10.1016/0014-4827(91)90368-5
227. Probstmeier R, Martini R, Tacke R, Schachner M. Expression of the adhesion molecules L1, N-CAM and J1/tenascin during development of the murine small intestine. Differentiation 1990; 44:42-55; http://dx.doi.org/10.1111/j.1432-0436.1990.tb00535.x
228. Zhao Y, Young SL. Tenascin in rat lung development: in situ localization and cellular sources. Am J Physiol 1995; 269:L482-91
229. LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem 1994; 269:20757-63
230. Talts JF, Eng H, Zhang HY, Faissner A, Ekblom P. Characterization of monoclonal antibodies against tenascin-C: no apparent effect on kidney development in vitro. Int J Dev Biol 1997; 41:39-48
231. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983; 43:2796-805
232. Aukhil I, Joshi P, Yan Y, Erickson HP. Cell-and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. J Biol Chem 1993; 268:2542-53
233. Carnemolla B, Borsi L, Bannikov G, Troyanovsky S, Zardi L. Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumorderived cell lines. Eur J Biochem 1992; 205:561-7
234. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 1993; 332:39-43; http://dx.doi.org/10.1016/0014-5793(93)80479-E
235. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, Humphrey PA. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol 1993; 24:982-9; http://dx.doi.org/10.1016/0046-8177(93)90112-T
236. Wilson KE, Langdon SP, Lessells AM, Miller WR. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 1996; 74:999-1004; http://dx.doi.org/10.1038/bjc.1996.480
237. Vollmer G, Tan MI, Wunsche W, Frank K. Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-b. Biochem Cell Biol 1997; 75:759-69
238. Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T, Sakakura T. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 1998; 77:98-102; http://dx.doi.org/10.1038/bjc.1998.15
239. Ghert MA, Jung ST, Qi W, Harrelson JM, Erickson HP, Block JA, Scully SP. The clinical significance of tenascin-C splice variant expression in chondrosarcoma. Oncology 2001; 61:306-14; http://dx.doi.org/10.1159/000055338
240. Levy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, Leroy K, Wechsler J, Salmon I, Wolkenstein P, et al. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007; 13:398-407; http://dx.doi.org/10.1158/1078-0432.CCR-06-0182
241. Paasinen-Sohns A, Kaariainen E, Yin M, Jarvinen K, Nummela P, Holtta E. Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase. Int J Biochem Cell Biol 2011; 43:441-54; http://dx.doi.org/10.1016/j.biocel.2010.11.018
242. Sakai T, Kawakatsu H, Hirota N, Yokoyama T, Takoka T, Sakakura T, Saito M. Tenascin expression in vitro and in vivo: comparison between epithelial and nonepithelial rat cell lines. Exp Cell Res 1993; 206:244-54; http://dx.doi.org/10.1006/excr.1993.1144
243. Dang C, Gottschling M, Roewert J, Forschner T, Stockfleth E, Nindl I. Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol 2006; 155:763-70; http://dx.doi.org/10.1111/j.1365-2133.2006.07401.x
244. Katz S, Hukkanen M, Lounatmaa K, Rousselle P, Tervo T, Virtanen I. Cooperation of isoforms of laminin-332 and tenascin-CL during early adhesion and spreading of immortalized human corneal epithelial cells. Exp Eye Res 2006; 83:1412-22; http://dx.doi.org/10.1016/j.exer.2006.07.021
245. Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G, Voutsinas G, Balafoutas D, Patsouris E. Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma. Exp Mol Pathol 2006; 80:177-82; http://dx.doi.org/10.1016/j.yexmp.2005.09.006
246. Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 2011; 20:685-8; http://dx.doi.org/10.1111/j.1600-0625.2011.01314.x
247. Galler K, Junker K, Franz M, Hentschel J, Richter P, Gajda M, Gohlert A, von Eggeling F, Heller R, Giavazzi R, et al. Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem Cell Biol 2012; 137:195-204; http://dx.doi.org/10.1007/s00418-011-0886-z
248. Nies DE, Hemesath TJ, Kim JH, Gulcher JR, Stefansson K. The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain protein containing unique epidermal growth factor repeats. J Biol Chem 1991; 266:2818-23